Januvia and Janumet: Merck’s Blockbuster Diabetes Drugs

Mike Benson - Author

May 12 2016, Updated 10:09 a.m. ET

Januvia and Janumet

Januvia and Janumet are Merck & Co.’s (MRK) blockbuster diabetes drugs. They’re used to lower blood sugar levels in patients with Type 2 diabetes. Combined sales for these drugs totaled ~$1.4 billion in 1Q16, a 4% growth at constant exchange rates, offset by a 3% negative impact of foreign exchange. This resulted in a 1.4% growth in revenues for these drugs in 1Q16 over 1Q15.

Article continues below advertisement
Article continues below advertisement

What makes Januvia and Janumet top sellers?

Januvia and its combination version Janumet are drugs classified as DPP-4 (dipeptidyl peptidase-4) inhibitors. DPP-4 is an enzyme that removes incretin from the human body for people without Type 2 diabetes. People with Type 2 diabetes use DPP-4 inhibitors to lower their blood sugar levels. DPP-4 inhibitors sometimes prevent weight gain in Type 2 diabetes patients.

Competitors for Januvia and its combination version Janumet are Onglyza, jointly manufactured by Bristol-Myers Squibb (BMY) and AstraZeneca (AZN), and Galvus by Novartis (NVS). Recently, Januvia was confirmed for a high safety profile and no risk of major adverse cardiovascular events or hospitalization for heart failure by the American Diabetes Association. There were a few concerns in the safety profile for Onglyza, according to an FDA (U.S. Food and Drug Administration) report.

Merck has also received marketing authorization for Marizev in Japan. Marizev is a once-weekly DPP-4 inhibitor.

Contribution of Januvia and Janumet

Januvia and Janumet together contributed about 15.2% of Merck’s total revenues for 1Q16, a ~0.4% increase over 1Q15 in terms of contribution. These drugs are estimated to contribute ~15.9% of total revenues for 2Q16, and 15.7% of total revenues for 3Q16, reflecting a positive trend.

For US markets, Januvia holds a 75% market share. Revenues increased 9% due to increased demand and the buying pattern of a few customers. Outside the US markets, Januvia holds a 65% market share. Reported growth in Europe and Japan was partially offset by lower sales in emerging markets and Venezuela. Revenues increased 5% outside the US markets, excluding Venezuela.

To avoid risk, investors can consider ETFs such as the SPDR S&P Pharmaceuticals ETF (XPH), which holds ~4.6% of its total assets in Merck.


Latest Bristol-Myers Squibb Co. News and Updates

    Opt-out of personalized ads

    © Copyright 2023 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.